This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
Skip to main content
United Kingdom | EN-GB

Add a bookmark to get started

Cortex - Life Sciences Insights

| less than a minute read

Checkpoint Inhibitors and Diabetes

PD-L1 and checkpoint inhibitors have been front and center in the media relating to the treatment of cancer.  Researches are now looking at the association with diabetes and metabolic disease.

In patients with Type 1 diabetes, T cells in the immune system mistakenly attack islet cells in the pancreas that make insulin. Scientists at Boston Children’s Hospital have come up with a way to thwart this wayward autoimmune reaction, and it involves a protein that plays a prominent role in new immunotherapy treatments for cancer: PD-L1.


life science, ipt, usa, checkpoint inhibitors, diabetes, pd-l1